Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Institutional & Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Alpha Cognition and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Alpha Cognition and Eloxx Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
| Eloxx Pharmaceuticals | 1 | 0 | 3 | 2 | 3.00 |
Alpha Cognition currently has a consensus price target of $18.00, suggesting a potential upside of 113.02%. Eloxx Pharmaceuticals has a consensus price target of $38.33, suggesting a potential upside of 179.81%. Given Eloxx Pharmaceuticals’ higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Alpha Cognition.
Valuation and Earnings
This table compares Alpha Cognition and Eloxx Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Cognition | $10.22 million | 18.01 | -$20.67 million | ($1.10) | -7.68 |
| Eloxx Pharmaceuticals | $6.36 million | 8.70 | -$5.99 million | ($1.54) | -8.90 |
Eloxx Pharmaceuticals has lower revenue, but higher earnings than Alpha Cognition. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Alpha Cognition has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, indicating that its stock price is 196,142% less volatile than the S&P 500.
Summary
Eloxx Pharmaceuticals beats Alpha Cognition on 8 of the 14 factors compared between the two stocks.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
